Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.01007-26 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Koji Ohyama und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. Hauptthemen laut MEDLINE: beta-Lactamases, Bacterial Proteins, Enterobacteriaceae Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi, NCGM Intramural Research Fund, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Carbapenem-resistant Enterobacterales (CRE) pose a global threat due to limited treatment options and high mortality. Difficult-to-treat resistance (DTR), defined as non-susceptibility to all conventional β-lactams and fluoroquinolones, has primarily been applied to Pseudomonas aeruginosa . However, its relevance for Enterobacterales remains unclear, particularly in regions with a distinct carbapenemase landscape, such as Japan where IMP-type metallo-β-lactamases predominate. We analyzed the MultiDrug-Resistant organisms clinical research network (MDRnet) cohort, a multicenter prospective study conducted at 13 Japanese hospitals between April 2019 and March 2024. This analysis included patients with clinically indicated cultures yielding CRE. Clinical characteristics and outcomes assessed using the desirability of outcome ranking (DOOR) framework and genomic epidemiology characterized by whole-genome sequencing were compared between DTR and non-DTR groups. Among 196 CRE cases, 64 (32.7%) represented infections, including 12 DTR cases (18.8%). Carbapenemase genes were detected in 34/64 infections (53.1%), with similar prevalence in the DTR and non-DTR groups (50.0% vs 53.8%). bla IMP-1 was the most frequently identified carbapenemase gene ( n = 28). The overall 30-day mortality rate was 21.9%, with 16.7% (95% confidence interval [CI], 2.1%–48.4%) in the DTR group and 23.1% (95% CI, 12.5%–36.8%) in the non-DTR group. DOOR outcomes were similar between groups. Appropriate empiric and definitive therapy was less frequently administered in the DTR group. In this cohort, where IMP-type carbapenemases and non-DTR CRE are prevalent, DTR classification did not appear to correlate with 30-day mortality or DOOR outcomes. These findings underscore the importance of regional molecular epidemiology when interpreting clinical outcomes of CRE infections. IMPORTANCE Difficult-to-treat resistance (DTR) is increasingly used to assess the clinical impact of antimicrobial resistance, but its significance in carbapenem-resistant Enterobacterales (CRE) may vary across molecular epidemiologic settings. In this prospective multicenter study from Japan, where IMP-type carbapenemases predominated, most CRE infections were classified as non-DTR. Whole-genome sequencing also revealed a distinct local clonal structure. DTR was not associated with 30-day mortality or desirability of outcome ranking despite lower rates of appropriate empiric and definitive therapy. Our study highlights the importance of interpreting DTR in CRE within the context of regional molecular epidemiology and supports the need for continued regional multicenter studies to evaluate its clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Biostatistics and Bioinformatics Course, The University of Tokyo, Bunkyo City, Tokyo, Japan.
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan.
- Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Kanagawa, Japan.
- Division of Infectious Disease and Hospital Epidemiology, Saga University Hospital, Saga, Japan.
ORCID-Profile: Koji Ohyama, Yasufumi Matsumura, Ryota Hase, Takashi Matono, Naoya Itoh, Go Yamamoto, Takeya Tsutsumi, Tetsuya Suzuki, Masahiro Suzuki, Aki Sakurai, Yusuke Asai, Shinya Tsuzuki, Kayoko Hayakawa, David van Duin, Norio Ohmagari, Yohei Doi, Sho Saito
Förderung
- Shionogi
- NCGM Intramural Research Fund
- Japan Society for the Promotion of Science
Zitieren
APA
Ohyama, K., Uemura, K., Matsumura, Y., Hase, R., Kato, H., Matono, T., Itoh, N., Hashimoto, T., Yamamoto, G., Mawatari, M., Tsutsumi, T., Suzuki, T., Suzuki, M., Hosoda, T., Sakurai, A., Asai, Y., Tsuzuki, S., Hayakawa, K., van Duin, D., …, & Saito, S. (2026). Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01007-26
Vancouver
Ohyama K, Uemura K, Matsumura Y, Hase R, Kato H, Matono T, et al. Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan. Microbiology Spectrum. 2026. doi:10.1128/spectrum.01007-26
BibTeX
@article{Ohyama2026,
author = {Ohyama, Koji and Uemura, Kohei and Matsumura, Yasufumi and Hase, Ryota and Kato, Hideaki and Matono, Takashi and Itoh, Naoya and Hashimoto, Takehiro and Yamamoto, Go and Mawatari, Momoko and Tsutsumi, Takeya and Suzuki, Tetsuya and Suzuki, Masahiro and Hosoda, Takuya and Sakurai, Aki and Asai, Yusuke and Tsuzuki, Shinya and Hayakawa, Kayoko and van Duin, David and Ohmagari, Norio and Doi, Yohei and Saito, Sho},
title = {Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.01007-26}
}
EUVIMED